A Phase 1 Trial of CNDO-109–Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia
Todd A. Fehniger, Jeffrey S. Miller, Robert K. Stuart, Sarah Cooley, Amandeep Salhotra, Julie Curtsinger, Peter Westervelt, John F. DiPersio, Timothy M. Hillman, Nova Silver, Michael Szarek, Leonid Gorelik, Mark W. Lowdell, Eric Rowinsky
Dive into the research topics of 'A Phase 1 Trial of CNDO-109–Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia'. Together they form a unique fingerprint.